

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 34134

Title: Nab Paclitaxel in pancreatic cancer: current evidences and future directions

Reviewer's code: 02441117

Reviewer's country: South Korea

Science editor: Ze-Mao Gong

Date sent for review: 2017-04-01

Date reviewed: 2017-04-18

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This review deals with the role of nab-paclitaxel in pancreatic cancer treatment. This extensive review especially included an updated and critical information about the role of nab-paclitaxel in pancreatic cancer treatment. The nab-paclitaxel is a recently introduced drug which combined with gemcitabine regarding as a standard therapy in unresectable pancreatic cancer treatment. This paper will be helpful and useful for readers who want to know current status and new findings about the role of nab-paclitaxel in pancreatic cancer treatment.

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 34134

Title: Nab Paclitaxel in pancreatic cancer: current evidences and future directions

Reviewer's code: 00503469

Reviewer's country: Netherlands

Science editor: Ze-Mao Gong

Date sent for review: 2017-05-05

Date reviewed: 2017-05-11

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This review includes important of information about the use of nab-paclitaxel for the treatment of pancreatic cancer , such as background of PDAC, chemoresistance , results of clinical trials, and so on. the text is well written and helpful for clinical practice. Therefore, this article is suitable for publication. I would suggest only minor revisions, including the addition of 1) a figure of the proposed drug mechanism of action 2) some references to recent reviews on similar topics showing: - some potential avenues for further development in the metastatic setting and current efforts to integrate new effective chemotherapy regimens such as neoadjuvant, adjuvant, and multimodal approaches in both resectable and unresectable patients: Metastatic pancreatic cancer: Is there a light at the end of the tunnel? Vaccaro V, Sperduti I, Vari S, Bria E, Melisi D, Garufi C, Nuzzo C, Scarpa A, Tortora G, Cognetti F, Reni M, Milella M. World J Gastroenterol. 2015 Apr 28;21(16):4788-801 - the potential role of new biomarkers, including miRNA, to improve the selection of both nab-paclitaxel and Folfirinox treatments in pancreatic cancer: FOLFIRINOX and translational studies: Towards



BAISHIDENG PUBLISHING GROUP INC

7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

personalized therapy in pancreatic cancer. Caparello C, Meijer LL, Garajova I, Falcone A, Le Large TY, Funel N, Kazemier G, Peters GJ, Vasile E, Giovannetti E. *World J Gastroenterol.* 2016 Aug 21;22(31):6987-7005.